Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
September 29, 2021
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone, and thank you for joining us for Palatin’s conference call covering operating results for the fourth quarter of fiscal year end 2021. Please note that this call is being recorded. Before we get into our prepared comments, I want to point out that anything Palatin says here that isn’t a historical fact could constitute a forward-looking statement. Such statements rest on assumptions that might turn out to be correct or might not, and actual outcomes could differ materially from what we anticipate because of the various risks and uncertainties described in the company’s latest filings with the Securities and Exchange Commission. We ask that you weigh those risks and uncertainties carefully as you evaluate these forward-looking statements and Palatin’s prospects. At this point, I’ll hand the call to our host, Dr. Carl Spana, Palatin’s President and Chief Executive Officer.
Carl Spana
executiveThanks. Morning, everyone, and thanks for joining Palatin Technologies' call covering the fourth quarter and the close of fiscal year 2021. This is Dr. Carl Spana, Palatin's CEO and President. Joining me today is Steve Wills, our Executive Vice President, Chief Financial Officer and Chief Operating Officer. During this call, we'll share updates on both finances and operations. At this point I'll hand things to Steve so he can walk through the financial updates. Steve?
Steve Wills
executiveThanks, Carl, and good morning, everyone. To set the frame — and Carl will go into more detail on this — Palatin's strategy is to move forward our melanocortin-based anti-inflammatory and autoimmune programs with a focus on ocular. As for Vyleesi, which holds FDA approval for treating hypoactive sexual desire disorder, or HSDD, in premenopausal women, what we aim to do with this program is show value in the marketplace by boosting awareness among healthcare providers, patient engagement, and market access, with the objective of relicensing the US rights to a committed women's healthcare company. And on progress, we are making progress, and this comes with a limited and measured investment. For the quarter ended June 30, 2021, gross product sales rose 28%, net revenue rose 149%, and total prescriptions rose 17% versus the quarter ended December 31, 2020, which is Palatin's first full quarter of Vyleesi operations. Refill rates went up compared with the quarters ended December 31, 2020, and March 31, 2021, and market access and reimbursement coverage also went up compared with the quarters ended December 31, 2020 and March 31, 2021. On revenue — and moving into our fourth quarter and fiscal year ended 2021 financial results; total net revenues were made up of net product revenues of Vyleesi and licensing contract revenue related to Vyleesi.
Steve Wills
executiveFor the quarter and the year that closed on June 30, 2021, Vyleesi gross sales came to $1.2 million and $4.7 million, respectively, while net product revenue — after allowances and accruals — was $80,504 and negative $283,286, respectively. For both the quarter and the year ending June 30, 2020, Palatin recorded no product revenues, since the product did not come back to us until July of 2020. Palatin did record $94,689 of license and contract revenues for the quarter and year ending June 30, 2021, tied to our license agreement with Kwangdong covering Vyleesi rights in South Korea; that compares with $117,989 for the year ended June 30, 2020 under our license agreement with AMAG Pharmaceuticals. As for operating expenses, they were $13.9 million for the quarter and $33.2 million for the year ended June 30, 2021, versus $7.4 million and $23.7 million, respectively, in the same periods of 2020. I'll go into a few of the other areas a little more, but those $13.9 million in operating expenses included roughly $4.5 million of an adjustment tied to terminating our license agreement with AMAG, and that item was non-cash and non-recurring. Operating expenses rose in 2021 mainly because of the recognition of non-cash expenses under the Vyleesi license termination agreement I just referred to, along with higher selling, general, and administrative expenses, which were largely commercialization-related costs for the Vyleesi program.
Steve Wills
executiveNow turning to net loss and cash flows. For Palatin, the net loss this quarter came in at $13.9 million and $33.6 million, or $0.06 and $0.14 per basic and diluted common share respectively — that's very close to operating expenses minus revenue. That compares with a net loss of $7.3 million and $22.4 million, or $0.03 and $0.10 per basic and diluted common share respectively, for the same period in 2020. As I said, looking just at operating expenses, the main difference for the quarter was the non-cash, non-recurring adjustment tied to the Vyleesi license termination agreement, plus some increases in selling and G&A, mainly from commercial expenditures for Vyleesi. Cash position — sorry, cash flows instead — Palatin's net cash used in operations for the quarter and year ended June 30, 2021 was $8.5 million. The main difference: we had operating expenses of $13.9 million and a net loss very close to that, and the reason net cash used in operations is significantly lower at $8.5 million is the roughly $4.5 million non-cash, non-recurring adjustment related to the Vyleesi termination agreement. We also had $22.6 million of net cash used in operations for the full fiscal year ended June 30, 2021, and that compares with net cash used in operations of $6.1 million and net cash provided by operations of $41.3 million positive cash provided there, respectively, for the same periods in 2020.
Steve Wills
executiveTurning to our cash position, at June 30, 2021, Palatin had $60.1 million in cash and cash equivalents plus $1.6 million in accounts receivable, versus $82.9 million in cash and cash equivalents and no accounts receivable at June 30, 2020. Under our current operating plan, we think the cash and cash equivalents we have on hand will be enough to fund anticipated operating expenses through the close of calendar '22. Carl will provide a little more detail, but this does cover the inflection points from the Phase 3 dry-eye disease trial data readout as well as the data readout from our ulcerative colitis Phase 2 trial during the second half of calendar '22. With that, I'll hand things back to Carl.
Carl Spana
executiveThank you, Steve. We're still operating under the conditions created by the COVID pandemic that continues. So far, the changes we've implemented have enabled us to keep moving forward with our preclinical, clinical, and commercial programs, all while safeguarding our employees, patients, healthcare providers, and partners. Once more, turning to our clinical and development programs, I want to stress the following points regarding our operating activities for Vyleesi. After Vyleesi came back to us last year, we carried out a thorough review of the Vyleesi commercial infrastructure and its activities. The results made it clear that a substantial makeover was required in order to support commercialization and relicensing of Vyleesi. This was no trivial or short-term undertaking. Under Steve's leadership, the Vyleesi commercial infrastructure has been rebuilt, and the changes implemented have dramatically enhanced the patient experience, patient access, relationships with prescribers, and the profitability of Vyleesi. We're now positioned to relicense Vyleesi to a committed partner, which ensures that Vyleesi remains available as a treatment option for premenopausal women with hypoactive sexual desire disorder and that our investment keeps delivering a return. At this point, I'd like to lay out some of the key objectives of our research and development program. Across a multitude of inflammatory and autoimmune diseases, there remains a vital medical need for new treatments that give patients and conditions safe and effective options.
Carl Spana
executiveWe’re focused on moving forward a new therapeutic approach for patients who have these inflammatory conditions, with the main emphasis on abdominal diseases—for example, diabetic retinopathy, dry eye, and uveitis—each of which draws on our distinctive knowledge and know-how and on creating medicines that modulate the melanocortin system. During the last 12 months, we’ve established the infrastructure for scientists in research and clinical development work that we think can successfully show the wide-ranging value of the melanocortin system as a target for many new effective drugs to treat these diseases. Our research scientists apply the newest techniques in genomics, proteomics, and cell biology to push forward our basic knowledge of how the melanocortin system resolves inflammation and encourages tissue healing. Findings from this work are already helping to steer our clinical development programs. Those clinical development programs mainly concentrate on creating melanocortin-based treatments for ocular indications. Even so, we’re also running small proof-of-concept studies for indications outside the eye. Such studies are meant to show the broad usefulness of the melanocortin system as a fresh target for drug development and to support our efforts to license our technology. Naturally, what we ultimately aim for is the creation of new, safe, and effective drugs that expand the treatment options available to patients.
Carl Spana
executiveAs we've mentioned, the melanocortin system is essential for shielding the eye against damaging inflammation, and we're working on several products based on melanocortin for ocular diseases. Our most advanced melanocortin agonist for treating ocular diseases affecting the tissues of the anterior segment—the front of the eye—is topically delivered PL9643. Dry eye disease is the first indication for PL9643, and as we reported before, we have positive data from our Phase 2 study. During the last quarter, we held a successful end of Phase 2 meeting with the FDA, at which we came to agreement on the key elements of the PL9643 Phase 3 clinical development program. Those include the patient population, the endpoints, and the clinical trial designs for the first of two Phase 3 pivotal registration studies. The first PL9643 Phase 3 dry eye disease study, known as Melody 1, will assess the safety and efficacy of PL9643 against vehicle control in patients who have moderate to severe dry eye disease across a 12-week treatment period. The trial is aimed at enrolling 240 patients, but it incorporates an interim data assessment to be carried out by an independent data monitoring committee, which will let us raise the subject count if necessary, thereby lowering the risk of an underpowered study.
Carl Spana
executiveThose 3 co-primary endpoints and 3 key secondary endpoints are going to be made up of the signs and symptoms of dry eye disease, and they were chosen after a detailed analysis of the Phase 2 data. Enrollment for Melody 1 starts in the fourth quarter of calendar 2021, with an interim data assessment in the first half of 2022, and we expect preliminary data early in the second half of 2022. Should that succeed, Palatin will launch the second Phase 3 PL9643 dry eye disease trial, known as Melody 2, along with an open-label safety study called Melody 3. If all goes well, those three Melody PL9643 dry eye studies will generate the safety and efficacy data needed for a new drug application filing with the FDA. PL9643's emerging profile — its rapid therapeutic onset along with excellent ocular tolerability and safety — represents a potentially distinct step forward in dry therapy. If the Phase 3 results hold up in the upcoming Phase 3 clinical study, we think PL9643 could achieve substantial penetration into the multi-billion dollar dry eye disease market. We also believe PL9643 and other melanocortin agonists will prove useful in treating other part of the eye diseases, and we plan to run a clinical study in a second front of the eye indication in the first half of 2022.
Carl Spana
executiveThe specific indication for this trial isn't settled just yet, though it's going to be determined by our research data along with clinical need. During the last 12 months, we've achieved meaningful progress in grasping how the melanocortin system might be leveraged to address diseases at the back of the eye, including diabetic retinopathy and macular edema, and work in preclinical models of retinal injury and diabetic retinopathy indicates that our PL9654, a melanocortin agonist, enhanced retinal Ophthalmology, shielded against photoreceptor cell loss and, crucially, preserved vision. Findings for PL9654 back moving it into clinical development, and right now we're focused on creating a sustained-release formulation of PL9654 that would be given through intravitreal injection—a widely used method for delivering drugs to treat retinopathies. Today's market for the range of retinopathy drugs exceeds $10 billion yearly and is expected to keep expanding. A substantial need persists for fresh, innovative retinal disease treatments, and we feel PL9654, even though it's early in development, holds tremendous potential to make a positive difference for patients with retinal disease and to capture a meaningful share of this very large and growing market. Alongside our ocular research and clinical development work, we've been running a broad communications push aimed at ophthalmologists and optometrists.
Carl Spana
executivePalatin’s scientists and collaborators have given presentations at nearly all the key medical conferences, and we’ve been actively publishing our research. Thanks to these efforts, Palatin is now starting to be seen as a company that is developing promising new therapies for ocular diseases. Turning to our oral PL8177 formulation for ulcerative colitis, we are carrying out the work needed to launch a Phase 2 proof of concept study, which aims for patient enrollment in the first half of 2022, with initial data readout in early second half 2022. This will be our first clinical trial intended to assess the potential of a selective melanocortin one receptor agonist as a treatment for ulcerative colitis. The study will assess the safety and efficacy of oral PL8177. If positive, the study results will further validate the melanocortin system as an innovative target for new drugs, and also support our efforts to license oral PL8177. The market for drugs treating various inflammatory bowel diseases is a multi-billion dollar one, and a large need remains for new, safe and effective treatment options to expand and advance treatment for these patients. The emerging safety and efficacy profile of oral PL8177, if confirmed, would be a potentially major advance in treating inflammatory bowel diseases, particularly in the pediatric patient population, where an extremely high unmet medical need remains.
Carl Spana
executiveAnd lastly, our natriuretic peptide program keeps moving forward with PL3994 — a selective natural peptide receptor A agonist — which is still enrolling patients in a Phase 2A clinical study involving heart disease patients who have preserved ejection fraction. That clinical study is running in cooperation with two major academic medical centers, and a grant from the American Heart Association is supporting it. We expect preliminary data from this study to be available in early 2022. Now, that was just a small snapshot of a few of the very exciting programs we're doing at Palatin, and you can certainly find more in additional information on our website, www.palatin.com. In closing, the past year has been transformative for Palatin, and a little over a year ago, with return of Vyleesi, we were a company with a single female health product in need of a major overhaul and some very early but interesting preclinical programs. As we began fiscal year 2022, we are a different company, advancing a new mechanism for treating a variety of inflammatory and autoimmune diseases based on drugs that modulating the melanocortin system, the focus on ocular diseases. With our first ocular melanocortin-based drug PL9643, we'll start a Phase 3 dry eye disease study before calendar yearend.
Carl Spana
executiveWe're also moving PL9654 forward in the drug development process, where it would be used to treat retinal diseases. Each of these innovative drugs could become a major player in markets that are growing and worth multiple billions of dollars. In addition, we intend to bring a second front of the eye disease program into clinical trials during the first half of 2022. What underpins this transformation is our distinctive grasp of the melanocortin system, together with our experience developing and gaining approval for drugs that modulate that system. During the past year, we've established infrastructure, brought in scientists and launched research activities that deepen our knowledge of how the melanocortin system operates, and those results are already informing our clinical programs. We're still on schedule to begin our Phase 2 proof of concept clinical study of the oral formulation of PL8177 in the first half of 2022, with data expected later that year. With Steve Wills leading the way, our Vyleesi commercial efforts have achieved meaningful progress. These changes are starting to produce a favorable effect — raising Vyleesi's prescriptions, revenue and prescription refills — and we expect to realize Vyleesi by calendar year end. To wrap up, as we head into 2022, Steve and I are enthusiastic about the enormous chance we have to push forward innovative drugs that will make a positive difference for patients and create shareholder value.
Carl Spana
executiveWe appreciate you joining us on this call and for your ongoing support of it. We will now open the line for questions.
Operator
operatorThanks. <<operator_script>> Our first question comes from Joe Pantginis at H.C. Wainwright.
Joe Pantginis
analystHi folks, appreciate you taking the question. So my question is really meant to center on 8177 for ulcerative colitis, though I suppose the rationale also speaks to your broader platform and the mechanisms of action tied to the underlying melanocortin system. So I guess first, could we begin with — when you look at 8177, in what ways can you contrast it against the commercial treatments available today? And I think a follow-up question could be, given that you have a differentiated mechanism of action, might there be any potential for combination capability that could help the competitive profile of the asset?
Carl Spana
executiveOkay, thanks, Joe. Let's figure out how to approach this in a straightforward manner. For sure, I believe the important things here are that you brought up how the mechanism of action differs. Something we appreciate about the melanocortin system is that we aren't shutting down a pathway responsible for inflammation. What we're doing is fundamentally aimed at resolving the inflammatory process that has been underway, that has become uncontrolled, and bringing it back under control. And as part of that, you actually get most of the (ph) tissue healing. One thing we observe with this mechanism is that you not only have the possibility of producing safety and efficacy, but it's quite safe. We aren't suppressing the immune system. So breakthrough infection, rare disease, rare inflammatory autoimmune conditions, or rare cancers really aren't expected to occur with this mechanism. So it's really quite safe. So from a positioning standpoint, look, we certainly can't speak to efficacy other than we have to access tremendous potential of course, but do we conduct clinical trials and begin to collect the data, we really can't answer that question in a lot of detail, but we do anticipate that we should see good efficacy based on the preclinical data.
Carl Spana
executiveOur expectation is that it would likely get used prior to transitioning to biologics. Ulcerative colitis, then, is yet another inflammatory condition that exists today. There's no current set of treatments that works effectively for a certain share of patients, but every one of them carries its own safety issues, worries, and tolerability problems. And typically, for a lot of patients, at some stage those choices start to lose effectiveness. So we truly expect to be positioned somewhere in the path that goes from generic therapies, perhaps after steroids, before you transition to a biologic. We're fairly enthusiastic given the safety (ph) — this is a peptide administered by mouth. There's no systemic absorption. We know that from the clinical studies we've already completed. So it's quite safe, and a really, really substantial need persists among the pediatric population, and we've been engaging with some of the key opinion leaders in that area. They're fairly enthusiastic about the potential of how this drug works. We genuinely do believe that in the pediatric population — which we plan to include those patients in, as soon as we have sufficient safety data to do so — we genuinely believe it could potentially become almost a first-line treatment for these patients, given safety and potential efficacy, so we're fairly enthusiastic about what we truly can accomplish with this.
Joe Pantginis
analystThat's helpful context, thank you. This may be premature to ask, but clearly your pipeline has grown broader now—one asset is close to moving into Phase 3, and earlier-stage assets are progressing. So at this stage, what's your aim when it comes to BD? Do you plan to out-license, hold on to certain territories, or what are your overall objectives at a high level right now?
Carl Spana
executiveSure. One point I really like to stress — and Steve and I have been doing this, and Steve made a start on it in his portion — is this: look, we have several very exciting programs, but what matters just as much is pushing that fundamental science forward. How does it — yes, our focus is in the ocular space, and we believe the potential there is tremendous, with multiple opportunities. You're starting to see that emerge — as you know, 18 months ago we had no ocular program at all and nothing in clinical trials, and now we're about to launch the first one in Phase 3, and that's pretty good. But the aim is like the ulcerative colitis, and we have another indication we'll add on — we'll tell you about it in — it's a non-orphan indication that we'll be adding. We'll discuss that on the next call. The real point is to demonstrate how broad this mechanism is. If we can put this treatment modality on the map, then you're talking about an entirely new treatment modality for inflammatory and autoimmune diseases. That will help a great many patients, and it will be tremendously valuable for our shareholders.
Carl Spana
executiveSo that's really the longer-term objective, but for ulcerative colitis, we wouldn't move ahead. We want to license that program out. For dry eye disease and other ocular indications, if the conditions are right and the data supports it, we'd certainly like to hold onto those for a longer period if we can. But I think if we hit it out of the park, which I think we will, I'm sure there's going to be a great deal of interest, and as much as we might want to keep those programs, I think, I don't know that we'll have the chance to do that. I think there will be other larger companies that will want them and will be willing to pay quite a lot for them.
Joe Pantginis
analystUnderstood, understood. Appreciate all of that, and best of luck in the new fiscal year.
Operator
operatorOur following question comes from John Newman at Canaccord.
John Newman
analystHey everyone, thanks for taking my question. I'm just curious whether you could say a bit about how the Melody 1 study is designed specifically, and whether you've disclosed which signs and symptoms you'd want to examine in that study. Thanks.
Carl Spana
executiveNot at this point, though that will change shortly. Those details will go up before long. You'll see the protocol once it lands on clinicaltrials.gov, and it follows a fairly conventional format. The trial itself is structured as a standard dry eye disease study. First comes a run-in phase in which we confirm the diagnosis and verify that each participant satisfies every enrollment requirement. That means selecting people whose condition is moderate to severe. In the United States, dry eye trials are typically run in what people call an adverse environment — participants sit in a chamber designed to dry their eyes out. This approach is widely used to keep the patient group consistent, since we're dealing with a disease that varies a great deal, and standardizing helps us there. As you mentioned, we assess two categories of measures: signs and symptoms. Signs serve as evidence of the disease — things like inflammation at the front of the eye, redness, tear film breakup times, tear production, and similar markers. In this trial, we'll assess fluorescein staining of the cornea along with lissamine green staining of the conjunctiva.
Carl Spana
executiveSo those are going to be — and it'll be entirely — we will be examining regional ones, like inferior, and then total as well. So there are 3 staining endpoints that we'll be assessing. 2 of them will be primary, and 1 will be secondary. The primary sign is going to be ocular discomfort, and then the key secondaries will be — I think one is burning, and I've forgotten the other one. But there will be — there will be a component of ocular discomfort for the most part. And then we'll spell those out in the protocol, and we file it, and we'll include that in the press release when we stated.
John Newman
analystAnd then there's one more question: in the study, will you be looking at patients who've had experience with other agents for dry eye, or only patients who haven't yet been treated with other products? Thanks.
Carl Spana
executiveRight. So they need to rinse it out. We don’t include artificial tears in the trial and we don’t use them in the trial, but if those are washed out of the study, they can come in, provided they are on active treatment at that time. They will be permitted into the study. And the other thing you mentioned regarding design—one element we have that’s somewhat distinctive is, as you’re likely aware, though perhaps the audience isn’t, that your dry disease is multifactorial both in the region of the eye, the front of the eye that can cause it, as well as in the types of patients, their age, underlying immune status, and so forth, which as a drug developer we don’t always like, because it creates a lot of variability. And one way you counter that is by enrolling large numbers of patients in the studies. But what we were able to agree on with the agency is a somewhat unique design, which is that we have a well-powered study based on the 240 patients, but as history will tell you with dry eye disease studies, they don’t always turn out the way you want.
Carl Spana
executiveSo to safeguard ourselves and let us add more patients if necessary, we've actually incorporated something known as an interim data assessment. So we're not going to be analyzing the data statistically, examining how the endpoints are performing. What it does is look at the power calculation, which lets us figure out whether additional patients need to be enrolled. The last thing we want is to fall just short at 240 when putting 300 into the study would have gotten us there. And why does that matter? Because from an FDA regulatory standpoint, everything we're after is a statistical difference in the endpoint between controlled and active, with no measurement or attribution of clinical benefit. The agency doesn't require that. A statistical difference is all they look for. So you really want to make sure your study isn't underpowered, and if 120 more patients are needed to get there, you want to have the ability to do that. So we believe we're going to hit at 240, but should we need to add any more, we've already worked that out with the agency and we have a mechanism in place for doing so.
John Newman
analystAlright, thank you very much — that's great.
Operator
operatorAnd our next question comes from Michael Higgins at Ladenburg Thalmann.
Michael Higgins
analystHi guys, thanks for the questions. Congratulations on the continued progress with the pipeline. A couple of questions here. The first is a followup from John's question on the interim, just trying to get a sense here in the early days, you've not started the trial yet. We don't have the clinic trials right up in front of us, but just trying to get some sense for what we will see from the interim look, if at this point subject to change, of course, but at this point, if you're looking for issuing a press release of yes, interim DSMB is suggested to go forward increase in numbers would be highlighted at that point. But really the question is how much evidence would you provide at that point on the endpoints? Or do you expect just to say as I mentioned continuing as number of patients to change or not.
Carl Spana
executiveNo information will come back to us about whether you're reaching the target or not. The only thing they'll tell us is either keep the study as it stands at 240 and finish it, or they'll say to add 150 more patients to the study, or perhaps just a handful more patients? We suggest adding 50 more patients to this study, or 100 more patients to this study. So the first reason would be that the interim analysis took place and we're on track. We'll keep going to 240, or we'll increase by a certain number of patients. But past that point, they won't give us anything further, and the reason is that this isn't a data analysis. It's really just an assessment of power calculation. We don't want to incur any statistical hits for multiplicity. So it's purely there to guard against variability in these studies, which can be high. So we want to make sure enough patients are enrolled.
Michael Higgins
analystThat makes sense, thanks. I just want to get that clarified, and then I'd like to follow up on what you said regarding 3994 — congratulations on seeking that data. Really, in 2022, this has been a program with enormous upside that's largely been outside your control, what with the AJ grants and waiting for sites to begin and get moving and all of that. So it's been something of a slow roll. Now we have data coming here in roughly the next 6 months. Tell us what you're looking for, along with any feedback you've received so far about enrollments and how this study is coming along — thanks.
Carl Spana
executiveEnrollment has been okay—it's been slow. The study is really split into two parts. The first part involves gathering safety and hemodynamic data, and we should have that by year-end. The second part will then proceed to examine more of a form of that dynamic response. So we'll be looking at biopsy and other markers of improvement and cardiovascular function. The first part should be done pretty soon. I believe those patients have either already been enrolled or are identified and are in the process of enrolling. So once they finish, we'll get the data from the first part, which will be hemodynamic and which is really very important. It would be great to see the effects of 3994 on pulmonary capillary wedge pressure, because that's truly very important in these patients. And as I mentioned, for the second part, we should have data around mid-next year, which will be the markers of cardiovascular and improved markers of heart failure in these patients. And keep in mind, these are preserved ejection fraction patients, where the need is quite high. Now, in addition to that, just as a little preview of upcoming attractions, we'll have more information out early next year on our overall natural peptide program beyond 3994.
Carl Spana
executiveThere are some positive developments happening there, but the schedule leaves us room to really dig into that during this call.
Michael Higgins
analystUnderstood, and thanks for adding that detail. I appreciate it. Then one final question about Vyleesi. Clearly there’s a sizable difference between gross and net sales. So as we look toward ’22 and even the rest of this calendar year, how should we expect that difference to narrow? From an accounting perspective, and also from a stocking perspective, what’s still left before that difference narrows? Thank you.
Carl Spana
executiveRight. That's the goal, and we're not really trying to close that gap so much. What we're actually targeting — where we're putting our time and focus — is market access, to grow the coverage and the net ASP, so to speak. Given how limited our investment is, and to support that, the funding came from the termination agreement. We got $16.3 million from AMAG when the rights came back to us. Granted, we did take on some CMC obligations. But I don't expect a big difference between the fourth quarter — the portion of it that is 1231 — and the third quarter, whether that's the 30th or 930. We will — we are seeing improvements at the moment. We review things daily, and obviously we have full visibility into July and August. Every metric — be it refills, prescriptions, and, importantly, in our view the most meaningful metric, market access — the scripts coming through that are insured drug covered, which is my favorite number, Code 8, since when I look at the report and see a Code 8, I know we've got insured drug coverage. So the bulk of our focus isn't really on time as such; we're just zeroing in on that metric to push it higher.
Carl Spana
executiveWe feel good that the progress is visible, and that's the kind of progress required when you're relicensing with partners—they want to see what the data shows, whether they can extrapolate from it, whether they can reach a comfort level that in their hands, in the hands of the right partner, the infrastructure exists. They have a market access team that is obviously far, far larger in sales infrastructure than what we have. So we're comfortable with this measured and limited investment as we demonstrate progress. We have a very good whack. We do have a number of subsidies from a co-pay standpoint, but we're seeing plenty of positive trends, albeit at the healthcare providers, with new healthcare providers coming on and scripts going up. And again, market access is our primary metric, and it is improving. So hopefully that was responsive. I know it was a bit long there, Michael.
Michael Higgins
analystThat's fine. Excellent, really. Thanks for the feedback, everyone. And congratulations once more.
Operator
operatorThat brings today's Q&A portion to a close. Dr. Spana, at this point I'll hand the conference back over to you for any closing remarks or anything else you'd like to add.
Carl Spana
executiveWell, I just want to thank all of you for being on the call, and thanks to our analysts for the questions that help us shed more light on what we're doing. Steve and I look forward to continuing to keep you updated on our work, and I'd really say that the staff here and the people here, even while we're operating under pandemic conditions, there's a tremendous amount of excitement about what we can do. And we're really looking forward to 2022 and a number of maybe significant events that are going to happen with this company. So stay tuned, and have a great day.
Operator
operatorThat wraps up today's call. We appreciate everyone joining us. You can go ahead and disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.